Key result
Early multimodal, physiology-guided vasopressor therapy is recommended to manage vasoplegic syndrome.
Why the study?
Vasoplegic syndrome is a frequent, life-threatening complication after cardiac surgery with CPB, with uncertain optimal treatment sequencing and patient selection.
Early multimodal, physiology-guided vasopressor therapy targeting multiple pathophysiological pathways is recommended for the management of vasoplegic syndrome after cardiac surgery.
Answers are grounded in this paper and cite their sources.
Supports multimodal vasopressor strategy in post-cardiac surgery vasoplegia; extends risk-factor data but leaves open RCT confirmation.
Vasoplegic syndrome (VS) is a frequent and potentially life-threatening complication following cardiac surgery with cardiopulmonary bypass (CPB) and is associated with significant morbidity and mortality. It is characterized by persistent hypotension, low systemic vascular resistance, and preserved or elevated cardiac output despite adequate volume resuscitation. This narrative review provides a comprehensive and clinically focused synthesis of current evidence on the pathophysiology, risk factors, diagnosis, and perioperative management of VS. A structured literature search of the PubMed database was conducted, focusing on studies published from 2020 to 2026 and complemented by key landmark trials. The pathophysiology of VS is multifactorial, involving systemic inflammatory activation, excessive nitric oxide production, vasopressin depletion, dysregulation of the renin-angiotensin-aldosterone system, and impaired vascular responsiveness to catecholamines. Major risk factors include preoperative use of ACE inhibitors or angiotensin receptor blockers, impaired cardiac function, prolonged CPB duration, and complex surgical procedures. Early recognition and differentiation from other causes of perioperative shock are essential for timely management. Current therapeutic strategies emphasize a multimodal, physiology-guided approach combining catecholamines with non-adrenergic agents such as vasopressin, methylene blue, hydroxocobalamin, and angiotensin II, particularly in refractory cases. Emerging evidence supports early combination vasopressor strategies to improve hemodynamic stability and reduce catecholamine exposure. However, optimal treatment sequencing and patient selection remain uncertain. A structured, algorithm-based approach integrating early diagnosis, targeted therapies, and advanced hemodynamic monitoring may improve clinical outcomes. Further research is needed to refine diagnostic criteria, identify reliable biomarkers, and establish evidence-based management algorithms for VS in cardiac surgery.
No takes yet. Share an insight, caveat, or question.
Khallikane et al. (2026) conducted a review in Vasoplegic syndrome in cardiac surgery. Multimodal vasopressor therapy (vasopressin, methylene blue, hydroxocobalamin, angiotensin II) was evaluated. Early multimodal, physiology-guided therapy combining catecholamines with vasopressin, methylene blue, hydroxocobalamin, and angiotensin II is recommended to manage vasoplegic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: